Functional Excipients for the Formulation of Solid Oral Dosage Forms
Fully Formulated Conventional and Modified Release Film Coating Systems
Alphabetical Listing of All Products
Products by Excipient Functionality
Formulation Information for Specific Applications
Technical Information for Solid Oral Dosage Manufacturing Processes
Useful Tools for the Pharmaceutical Formulator
Technical formulation and development seminars and forums
Competitor, Consumer Color Preference, Regulatory, Tablet Library of Shapes, and Trademarks
Unique Tablet Designs and Branding Solutions
Concept to Prototypes using State-of-the-Art 3D Images and Models through our Tablet Design Centers
Understand Options and Learn of New Technologies to Protect your Brand
Global Technical Support, Technical Service Labs and Tablet Design Centers
Global Regulatory Support Services
Global Customer Support and Service Locations
Useful Tools to Assist Pharmaceutical Product Development
Extensive Collection of Articles, Product Literature, Application Data and Regulatory Documents
Technical Formulation and Development Seminars and Forums
Products
Acryl-EZE® 93A Product InformationFeatures and benefits of the Acryl-EZE 93A series of aqueous, acrylic enteric delayed release coating systems.
Acryl-EZE® Enteric Coating StabilityThis product data sheet provides stability information for Acryl-EZE coated, delayed release aspirin tablets, at ambient and accelerated storage conditions.
Acryl-EZE® MP Product InformationFeatures and benefits of the Acryl-EZE MP series of aqueous, acrylic enteric delayed release coating systems.
Acryl-EZE® Product StabilityThis product data-sheet provides stability information for reconstituted Acryl-EZE powder formulations at ambient and accelerated storage conditions.
Acryl-EZE® Coating ParametersRecommended coating process parameters for Acryl-EZE in laboratory, pilot, and production scale coating pans.
Acryl-EZE® MP Coating ParametersRecommended coating process parameters for Acryl-EZE MP in laboratory and pilot scale fluid bed coaters.
Acryl-EZE® 93A Preparation and Use SheetOutline of the recommended dispersion mixing procedures, coating levels, and cleaning guidelines for the Acryl-EZE 93A series.
Acryl-EZE® MP Preparation and Use SheetOutline of the recommended dispersion mixing procedures, coating levels, and cleaning guidelines for Acryl-EZE MP.
Acryl-EZE® Preparation and Use SheetOutline of the recommended dispersion mixing procedures, coating levels, and cleaning guidelines for Acryl-EZE.
Acryl-EZE® Product BrochureIntroduction to the Acryl-EZE platform of delayed release coating systems.
Acryl-EZE® Optimal Coating ParametersThis poster reprint outlines the optimum coating process parameters for Acryl-EZE dispersions..
Application of Acryl-EZE® 93F on Rabeprazole Sodium Tablets (20 mg) This poster reprint demonstrates the successful use of Acryl-EZE 93F19255, when applied onto rabeprazole sodium tablets.
Application of Powder Layering Technology and Aqueous Enteric CoatingThis poster reprint demonstrates the successful use of Acryl-EZE® 93F19255, when applied onto dry powder layered lansoprazole multiparticulates.
Aqueous Enteric Coating Application on Non-Banded Hard Gelatin Capsules This poster reprint investigates the delayed release performance of Acryl-EZE® 93F19255, when applied onto omeprazole filled, hard gelatin capsules.
Controlled Permeability Films for Programmable Drug ReleaseThis poster reprint investigates the influence of sodium alginate or hypromellose (HPMC) as pore formers in a delayed release film coating to achieve modified enteric drug release.
Enteric Coating of Tablets with Debossed LogosThis poster reprint demonstrates how to successfully enteric coat tablets which contain a debossed logo.
Investigation of a Modified USP Disintegration Test Method for Enteric Coated TabletsThis poster reprint outlines the method and rationale for the analysis of enteric-coated dosage forms in intermediate acidic pH conditions (pH 4.5).
New Coating Process for the Application of Enteric Coatings to Small Tablet SamplesThis poster reprint investigates the rapid application of an aqueous enteric coating system onto very small batch sizes of tablets using a novel coating process technology, the SUPERCELL™ process from Niro.
Performance Characteristics of Acryl-EZE®This poster reprint compares the performance of the Acryl-EZE fully formulated system versus a multiple step dispersion preparation of Eudragit L100-55.
Preparation of Robust, Enteric-Coated Dosage Forms Utilizing Acryl-EZE®This poster reprint provides solutions for the application of aluminum lake pigmented Acryl-EZE formulations onto various actives, to provide stable, reproducible drug release.
Preparation of Stable, Gastro-Resistant Diclofenac Sodium Tablets, Utilizing Optimized Film-Coating Combinations with Acryl-EZE®This poster reprint demonstrates how to reduce your overall coating process time and achieve drug product stability, by incorporating pigments directly into the Acryl-EZE enteric film layer.
Preparation of an Enteric Dosage Form with a Water-Dispersible Acrylic Film Coating FormulationThis poster reprint provides stability information for the Acryl-EZE® formulation as well as Acryl-EZE, enteric-coated aspirin tablets.
Production-Scale Process and Performance Comparison of Two Fully-Formulated Aqueous Enteric Coating SystemsThis poster reprint summarizes the production scale evaluation of Acryl-EZE® and Sureteric® for coating process, enteric protection, and finished product stability.
The Effect of Superdisintegrant on Acid Resistance of Enteric Coated TabletsThis poster reprint investigates the influence of superdisintegrant type and level on the performance of two enteric coated tablet formulations.
The Influence of Gastric Media (In-Vitro) on the Performance of Delayed Release Proton Pump Inhibitor Dosage FormsThis poster reprint investigates the enteric performance of aqueous enteric-coated tablet formulations containing proton pump inhibitors (PPI’s) in bio-relevant media, which better simulates the gastric environment of a patient on a multiple dose regimen of PPI’s.
The Influence of Plasticizer Type and Concentration on Acid Resistance of Tablets Coated with Acryl-EZE® 93AThis poster reprint investigates the influence of plasticizer type and concentration on acid resistance, when added to Acryl-EZE 93A, aqueous delayed-release (DR) film coating systems.
The Influence of Plasticizer Type and Concentration on Acid Resistance of Tablets Coated with a New Aqueous Delayed Release Film Coating SystemThis poster reprint investigates the influence of plasticizer type and concentration on acid resistance, when added to Acryl-EZE® 93A, aqueous delayed-release (DR) film coating systems.
Assure Tablet Formulation Regulatory ComplianceInformation sheet describing how the BEST® team utilizes the Global Regulatory Affairs Department at Colorcon®.
Brochure - The Art of Tablet DesignBrochure describing how BEST® combines market research, tablet design images, and tablet models to present superior possibilities for each tablet design project.
Finding the Right Market Research to Expedite Informed Tablet Design DecisionsInformation sheet describing the market research tools that inform BEST® tablet designs.
Maximize Trademark Potential for Color, Shape and Logo CombinationsInformation sheet explaining the advantages of trademark protection and describes how BEST® services can generate tablet designs with trademark potential.
Modern Tablet Film Coatings and Influence on Ease of SwallowingStudy that investigates esophageal transit times and incidence of transit delays in film-coated tablets versus uncoated tablets and gelatin capsules.
Cal-Carb® 4450 PGCal-Carb 4450 is an excipient granulation prepared from Calcium Carbonate USP and Maltodextrin NF.
Cal-Carb® 4457Cal-Carb 4457 is an excipient granulation prepared from Calcium Carbonate USP and Pregelatinized Starch.
Cal-Carb® 4462Cal-Carb 4462 is an excipient granulation prepared from precipitated Calcium Carbonate USP and Pregelatinized Starch.
ETHOCEL™ Sales BrochureIntroduction to the ETHOCEL line of premium ethylcellulose polymers.
Maintaining Similar Drug Release from Hypromellose Matrices with Identical Dimensions but Different Dose StrengthsThis poster reprint provides a method to maintain similar drug release, tablet shape and weight, from a METHOCEL™ matrix, while adjusting the drug dose.
An Introduction to METHOCEL™ Cellulose EthersA description of the METHOCEL line of premium cellulose ethers.
Blending for Intermediate ViscosityThis product data sheet demontrates how to blend existing viscosity grades of METHOCEL™ to obtain an intermediate viscosity grade.
General Properties of METHOCEL™ Premium Cellulose EthersThis product data sheet describes chemical and physical properties of METHOCEL premium cellulose ethers.
How to Prepare Aqueous Solutions of METHOCEL™This product data sheet describes how to prepare aqueous solutions of METHOCEL.
How to Prepare Solutions of METHOCEL™ in Nonaqueous SolventsThis product data sheet describes how to prepare solutions of METHOCEL from non-aqueous solvents.
HyperStart® Formulation Service: Predicting Performance and Accelerating DevelopmentIntroduction to the HyperStart formulation service for hydrophilic matrix systems.
Properties of Solutions of METHOCEL™This product data sheet describes the properties of METHOCEL solutions.
Using METHOCEL™ Cellulose Ethers for Controlled Release of Drugs in Hydrophilic Matrix SystemsThis product data summarizes the application of METHOCEL premium cellulose ethers in extended release, hydrophilic matrix formulations.
Controlled Release Alliance BrochurePromotional booklet which outlines the Colorcon/Dow Wolff Cellulosics Controlled Release Alliance.
METHOCEL™ Sales BrochureIntroduction to the METHOCEL platform of water soluble cellulose ethers.
Bi-Phasic Drug Release from Drug Layered, Extended Release Hypromellose MatricesThis poster reprint summarizes a process utilized to achieve an immediate and extended release profile from an HPMC matrix system.
Direct Compression Metformin HCl 500mg Extended Release Formula Based on HypromelloseThis poster reprint investigates the formulation of an extended release, direct compression Metformin HCl (500 mg) matrix tablet using METHOCEL™.
Evaluation of Verapamil HCl (240 mg) Extended Release Matrix Formulations This article reprint investigates the use of dissolution testing apparatus III and biorelevant dissolution media as a means to better understand the in-vivo release of drug from METHOCEL™ matrices.
Evaluation of the Effect of Hydroalcoholic Media on Textural and Rheological Characteristics of Hypromellose MatricesThis poster reprint investigates the effect of hydro-alcoholic dissolution media on the textural properties of METHOCEL™ matrices, and rheological properties of METHOCEL solutions.
Investigation of a Directly Compressible Hypromellose Matrix Formulation for a Low Dose, Practically Insoluble DrugThis poster reprint investigates the formulation of an extended release, direct compression Indapamide (1.5 mg) matrix tablet using METHOCEL™.
Investigation of a Venlafaxine HCl (37.5mg) Extended Release Formulation using Hypromellose (HPMC) MatricesPoster reprint which provides a method to minimize a burst of drug release typically observed in the early phases of release of highly soluble actives from METHOCEL™ matrices. Granulation of the drug, and coating on top of the matrix, with Surelease, were investigated.
Investigation of the Effects of Hydro-Alcoholic Media on Rheological and Textural Properties of Various Grades of Hypromellose (HPMC)This poster reprint expands on previously reported work which investigated the effect of hydro-alcoholic dissolution media on the textural properties of METHOCEL™ matrices, and rheological properties of METHOCEL solutions.
Mathematical Model for Simulation and Control of Drug Release from Hydrophilic MatricesThis poster reprint utilizes mathematical modeling to summarize the influence of several formulation variables on drug release from METHOCEL™ matrices.
Modulation of Drug Release from Hypromellose (HPMC) Matrices: Suppression of the Initial Burst EffectPoster reprint which provides a method to minimize a burst of drug release typically observed in the early phases of release of highly soluble actives from METHOCEL™ matrices.
Particle Swelling and Coalescence to Gel Layer FormationThis poster reprint investigates swelling and coalescence behaviour of hydroxypropylmethyl cellulose (HPMC) and partially pregelatinised starch particles, in order to monitor the contribution to gel layer formation in mixed HPMC and Starch 1500® matrices.
The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose MatricesThis poster reprint investigates the influence of three film coating systems on the performance of Metformin HCl (500mg) extended release (ER) Hypromellose matrices stored under different conditions up to 12 months.
The Effect of In-Vitro Dissolution Parameters on the Release Rate of a Low Dose, Low Solubility Drug from Extended Release Hypromellose Matrix Formulations This poster reprint examines the impact of dissolution testing parameters on a low dose, low solubility, METHOCEL™ matrix formulation, compared to a marketed reference product.
The Influence of Anionic Polymers on Hydrochlorothiazide Extended Release Hypromellose MatricesThis poster reprint summarizes the effect of blending anionic polymers (carbomer and polyvinyl acetate phthalate [PVAP, Phthalavin®]) with HPMC, on extending the release of a very slightly soluble drug (~1.0 mg/ml). The effects of varying the polymer blend ratio and excipient choice were studied in terms of drug release profile and textural properties of the hydrated matrix tablets.
The Influence of Film Coatings on Performance of Hypromellose MatricesPoster reprint which examines the influence of various immediate release film coatings on the drug release from METHOCEL™ matrices.
The Influence of Formulation Variables on Drug Release Kinetics from Hypromellose Extended Release MatricesThis poster reprint utilizes mathematical modeling to summarize the influence of several formulation variables on drug release from METHOCEL™ matrices.
The Influence of Hydro-Alcoholic Media on Hypromellose Matrix SystemsThis poster reprint investigates the effect of hydro-alcoholic dissolution media on the swelling and drug release properties of METHOCEL™ matrices.
The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240mg) Extended Release FormulationThis poster reprint examines the impact of the type of dissolution testing method on drug release from extended release verapamil hydrochloride METHOCEL™ matrices.
Application of a Modeling System in the Formulation of Extended Release Hydrophilic MatricesThis article reprint describes a predictive formulation service that provides pharmaceutical scientists with a starting formula for hydrophilic matrix tablets.
Excipient Update, Influence of fillers, compression force, film coating, and storage conditions on Performance of Hypromellose matricesInvestigates the influence of fillers, compression force, film coating, and storage conditions on performance of hypromellose matrices.
The Influence of Excipients on Drug Release from Hydroxypropyl Methylcellulose MatricesPublished article reprint that summarizes the influence of various excipient fillers on the drug release from METHOCEL™ matrices.
Nu-Tab® 4000 (no mag.)Nu-Tab 4000 (no mag.) is a granular and free-flowing tableting vehicle that exhibits the sweet taste of sucrose and can be use as a directly compressible diluent.
Nu-Tab® 4000 (with mag.)Nu-Tab 4000 (with mag.) is a granular and free-flowing tableting vehicle that exhibits the sweet taste of sucrose and can be use as a directly compressible diluent.
Nu-Tab® 4001 (no Mag.)Nu-Tab 4001 (no mag.) is a white, granular and free-flowing tableting vehicle that exhibits the sweet taste of sucrose and is used as a directly compressible diluent.
Nu-Tab® 4001 (with mag.)Nu-Tab 4001 (with mag.) is a white, granular and free flowing tableting vehicle that exhibits the sweet taste of sucrose.
Nu-Tab® 4001A (with Mag.)Nu-Tab 4001A (with mag.) is a white, granular and free-flowing tableting vehicle that exhibits the sweet taste of sucrose and is used as a directly compressible diluent.
Nu-Tab® 4040Nu-Tab 4040 is a white granular and free-flowing tableting vehicle that exhibits the sweet taste of sucrose.
Nu-Tab® 4040 BFSNu-Tab 4040 BFS is a white, granular and free flowing tableting vehicle that exhibits the sweet taste of sucrose. Nu-Tab® 4040 BFS is specially formulated with bone-char free sugar.
Delayed Release Coating of Garlic Tablets with Nutrateric in a 24" Fully Perforated side vented pan (Accela-Cota® type) Recommendations for the application of Nutrateric onto garlic tablets in a side-vented coating pan.
Delayed Release Coatings for Nutritional Supplements using Nutrateric® ClearNurateric is an easy-to-use and reliable delayed release coating for nutritional supplements. This information sheet details the preparation, use and clean-up guidelines for this coating system
Delayed Release Coatings for Nutritional Supplements using Nutrateric® PigmentedOutline of the recommended dispersion mixing procedures, coating levels, and cleaning guidelines for Nutrateric.
Nutrateric® - Stability and Use GuidelinesSummary of Nutrateric dispersion characteristics and stability. Demonstration of enteric protection on garlic tablets.
Nutrateric® Sales BrochureIntroduction to the Nutrateric platform of delayed release coating systems.
New Enteric Coating System (Nutrateric®) for Nutritional SupplementsThis poster reprint summarizes the performance of Nutrateric when applied to tablets or soft gelatin capsules.
The Influence of Plasticizers and a Stabilizer on Aqueous Delayed Release (DR) Coating Systems on Soft Gelatin CapsulesThis poster reprint investigates the influence of different plasticizers and a secondary stabilizer (hypromellose, HPMC) in Nutrateric on the delayed release performance of coated fish oil soft gelatin capsules.
The Influence of a pH Dependent Pore Former on Acid Protection from Tablets Coated with an Aqueous Ethylcellulose Barrier MembraneThis poster reprint investigates the application of Nutrateric on aspirin and caffeine cores to achieve enteric protection.
Effectiveness of Moisture Barrier Coatings on Various Tablet CoresEvaluation of Opadry® AMB compared with alternative coating formulations and their effect on moisture uptake.
Opadry® AMB - Coating ConditionsStarting process recommendations for use of Opadry AMB.
Opadry® AMB - Moisture Vapor TransmissionEvaluation of Opadry AMB compared with alternative coating formulations and their effect on moisture uptake.
Opadry® AMB - Preparation and UseMixing procedure and holding instructions for Opadry AMB coating formulations.
Opadry® AMB Sales BrochureProduct features and benefits.
Correlation of Free Salicylic Acid Content to the Water Vapor Transmission Properties of Aqueous Film Coating SystemsEffective moisture protection of a solid oral dosage from an aqueous film coating system.
Opadry® Enteric Product InformationFeatures and benefits of the Opadry Enteric platform of PVAP (Phthalavin®) based, delayed release coating systems.
Opadry® Enteric Preparation and Use SheetOutline of the recommended dispersion mixing procedures, coating levels, and cleaning guidelines for the Opadry Enteric 91 series.
Opadry® Enteric Sales BrochureIntroduction to the Opadry Enteric platform of PVAP (Phthalavin®) based, delayed release coating systems.
Hydro-Alcoholic Applications of Polyvinyl Acetate Phthalate (PVAP) for Oral Delayed Release Coating SystemsThe objective of this poster reprint was to examine the gastro-resistance and drug release of diclofenac sodium tablets and omeprazole multi-particulates (MP) coated with Opadry® Enteric, using hydro-alcoholic solutions.
The Influence of Solvent System on the Performance of Polyvinyl Acetate Phthalate (PVAP) Delayed Release Coating SystemsThis poster reprint provides the dispersion characteristics and coating process parameters for an Opadry® Enteric system, when prepared in different solvent mixtures.
Coating Process Conditions - 85 F Series - Clear FormulaTypical processing conditions - side vented fully perforated and convention pans.
Opadry® II - Preparation and Use Mixing procedure and holding instructions for Opadry II coating formulations.
Opadry® II - Sales BrochureImproved efficiency PVA and HPMC coating formulations reduce coating processing time by 25-30% compared with conventional systems. For use in nutritional and pharmacuetical applications.
Coating Moisture-Sensitive Products Influence of inlet temperature and airflow on moisture uptake by tablet cores using a PVA-based film coating system.
Effect of Coating Process Conditions and Coating Formula Type on the Quantity and Location of Water in Film-Coated TabletsEffects of process conditions and formula type on tablet moisture gain.
Evaluation of a Film Coating that Produces Enhanced Tablet-to-Tablet Film Uniformity In this study, Opadry® II (85 series) Clear was shown to have lower coating weight gain standard deviations than a standard clear hypromellose based film coating. Pigmented Opadry II (85 series) achieved similar or better coating color uniformity with a 1/3 savings in processing time.
Investigation into the Flow Properties of Coated and Uncoated Tablets and its Relevance to Blister Packing Efficiency Reduce contamination and improve packaging line efficiency through the application of a fully formulated film coating. Realize improved yield when packaging pharmaceutical or dietary supplement products.
Protection and Processing of a Highly Hygroscopic Herbal Extract by Drug Layering and Film CoatingStudy of the stablity improvements for Echinacea Purpurea beads layered with a moisture PVA and HPMC based barrier film coating.
Reducing Coated Tablet Defects from Laboratory Through Production Scale: Performance of Hypromellose Based and Polyvinyl Alcohol Based Aqueous Film Coating SystemsZero Defects, Less Time, Less Material as a result of Opadry® II coating innovation from Colorcon®.
Opadry® tm - Taste Mask ComparisonProduct technology summary including stability profile, film properties, color effects and regulatory guidelines.
Opadry® tm - Sales BrochureProduct features and benefits.
Taste Masking Performance and Stability of Opadry® tmTaste and dissolution profile studies of Bitrex and Caffeine tablet cores coated with Opadry tm.
Opadry® fx™ PropertiesProduct technology summary including stability profile, film properties, color effects and regulatory guidelines.
Reconstitution SheetMixing and holding instructions for Opadry® fx suspensions.
Opadry® fx™ Sales BrochureProduct features and benefits.
Opadry® fx™ Enhanced Moisture Protection and Film PropertiesCharacterization of moisture vapor transmission rate and other film properties of Opadry fx.
Effect of Tablet Shape on the Perception of High Gloss Film Coating SystemsPoster study on the importance of tablet shape selection in the development of dosage forms with a high gloss finish.
Opaglos® 2 Gloss Units ComparisonGloss comparison of commercially available product compared with Opaglos 2 tablets.
Opaglos® 2 Powder Stability Summary of the analytical and microbiological stability data of Opaglos 2 dry powder.
Opaglos® 2 Reconstitution Procedure Mixing procedure and holding instructions for Opaglos 2 coating formulations.
Opaglos® 2 Sales BrochureProduct features and benefits.
Determination of Critical Process Parameters on the Application of an Aqueous, High Gloss Film Coating SystemCritical process parameters for achieving an elegant high-gloss film coating.
Enhanced Aesthetic and Functional Stability of Opaglos® 2 High Gloss Film Coating System vs. Sugar CoatingAchieving the elegance of a sugar coated dosage with an aqueous film coating.
Photostability of Pharmaceutical Colorants in Opaglos® 2Assesment of the relative color stability of Opaglos 2 formulations containing iron oxides or Red #40, Yellow #6, Blue #2 (Dye or Lakes).
Physical Properties and Stability of Opaglos® 2, a Pigmentable High Gloss Film Coating SystemStudy comparing free film performance, rheological properties and dissolution profiles of Opaglos 2 to other cellulosic polymer-based film coatings on both acetaminophen and ibuprofen coated tablet cores.
Stability of Acetaminophen 500mg Cores Coated with Opaglos® 2Disintegraton and dissolution stability results for Acetaminophen cores coated with Opaglos 2.
Stability of Ibuprofen 200mg Cores Coated with Opaglos® 2Disintegraton and dissolution stability results for Ibuprofen cores coated with Opaglos 2.
Opalux® Tablet Sealant CoatingProduct Overivew.
